Evidence mapPaperPMID 39377487Full record

ArticleJournal of extracellular vesicles2024

Small RNAs in plasma extracellular vesicles define biomarkers of premanifest changes in Huntington's disease.

Marina Herrero-Lorenzo, Jesús Pérez-Pérez, Georgia Escaramís, Saül Martínez-Horta, Rocío Pérez-González, Elisa Rivas-Asensio, Jaime Kulisevsky, Ana Gámez-Valero, Eulàlia Martí

Abstract read
In one paragraph

Article in Journal of extracellular vesicles, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 9 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
9citing papers in PubMed, 1 pooled it
field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

9 citing papers in PubMed, 1 synthesis or guideline pooled it.

  1. Pooled it
  2. Article
  3. Article
  4. Article
  5. Article
  6. Article
  7. Review
  8. Article
  9. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors.

Marina Herrero-LorenzoDepartment of Biomedicine, Faculty of Medicine, Institute of Neurosciences, University of Barcelona, Barcelona, Catalunya, Spain.ORCID 0000-0003-2693-0700
Jesús Pérez-PérezMovement Disorders Unit, Neurology Department, Sant Pau Hospital, Barcelona, Catalunya, Spain.ORCID 0000-0002-9835-0484
Georgia EscaramísDepartment of Biomedicine, Faculty of Medicine, Institute of Neurosciences, University of Barcelona, Barcelona, Catalunya, Spain.ORCID 0000-0002-5416-3177
Saül Martínez-HortaMovement Disorders Unit, Neurology Department, Sant Pau Hospital, Barcelona, Catalunya, Spain.ORCID 0000-0003-0125-7249
Rocío Pérez-GonzálezMovement Disorders Unit, Neurology Department, Sant Pau Hospital, Barcelona, Catalunya, Spain.ORCID 0000-0002-0641-2001
Elisa Rivas-AsensioMovement Disorders Unit, Neurology Department, Sant Pau Hospital, Barcelona, Catalunya, Spain.
Jaime KulisevskyMovement Disorders Unit, Neurology Department, Sant Pau Hospital, Barcelona, Catalunya, Spain.ORCID 0000-0003-4870-1431
Ana Gámez-ValeroDepartment of Biomedicine, Faculty of Medicine, Institute of Neurosciences, University of Barcelona, Barcelona, Catalunya, Spain.ORCID 0000-0002-9530-2751
Eulàlia MartíDepartment of Biomedicine, Faculty of Medicine, Institute of Neurosciences, University of Barcelona, Barcelona, Catalunya, Spain.ORCID 0000-0002-1030-3158

Funding

Huntington's Disease Society of America (HDSA) 2021 Human Biology ProjectPhD Fellowship Spanish Ministry of Science and Innovation PRE2018-085617Postdoctoral fellowship Juan de la Cierva FJC2019-039633-ISpanish Carlos III Health Institute (ISCIII) PI121/01758Spanish Carlos III Health Institute (ISCIII) PI17/01885Spanish Ministry of Science and Innovation AEI/10.13039/501100011033Spanish Ministry of Science and Innovation PID2020-113953RB-I00
6 · The paper itself

Abstract

Despite the advances in the understanding of Huntington's disease (HD), there is a need for molecular biomarkers to categorize mutation carriers during the preclinical stage of the disease preceding functional decline. Small RNAs (sRNAs) are a promising source of biomarkers since their expression levels are highly sensitive to pathobiological processes. Here, using an optimized method for plasma extracellular vesicles (EVs) purification and an exhaustive analysis pipeline of sRNA sequencing data, we show that EV-sRNAs are downregulated early in mutation carriers and that this deregulation is associated with premanifest cognitive performance. Seven candidate sRNAs (tRF-Glu-CTC, tRF-Gly-GCC, miR-451a, miR-21-5p, miR-26a-5p, miR-27a-3p and let7a-5p) were validated in additional subjects, showing a significant diagnostic accuracy at premanifest stages. Of these, miR-21-5p was significantly decreased over time in a longitudinal study; and miR-21-5p and miR-26a-5p levels correlated with cognitive changes in the premanifest cohort. In summary, the present results suggest that deregulated plasma EV-sRNAs define an early biosignature in mutation carriers with specific species highlighting the progression and cognitive changes occurring at the premanifest stage.

Indexed as

BiomarkersExtracellular VesiclesHuntington DiseaseMicroRNAsAdultFemaleHumansLongitudinal StudiesMaleMiddle AgedMutationBiomarkersMicroRNAsMIRN21 microRNA, humanbiomarkerextracellular vesiclesHuntington's diseasemiRNApremanifestsmall RNAtRF

Identifiers

PMID39377487
PMCPMC11633361

What Socratic holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.